Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
Authors
Keywords
bispecific anti-EGFR×MET antibody, non–small cell lung cancer (NSCLC), amivantamab, EGFR exon 20 insertion, MET amplification, combinatorial screening, crystal structure, epitope mapping
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume -, Issue -, Pages 100641
Publisher
Elsevier BV
Online
2021-04-08
DOI
10.1016/j.jbc.2021.100641
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis
- (2020) Smruthi Vijayaraghavan et al. MOLECULAR CANCER THERAPEUTICS
- A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
- (2018) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR- Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study
- (2018) Giorgio V. Scagliotti et al. Journal of Thoracic Oncology
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
- (2018) Bushra Husain et al. BIODRUGS
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer
- (2016) Bok-Soon Lee et al. ANNALS OF SURGICAL ONCOLOGY
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors
- (2016) Alexandra Gonzalez et al. INTERNATIONAL JOURNAL OF CANCER
- Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
- (2016) Katharine D. Grugan et al. mAbs
- Novel strategy for a bispecific antibody: induction of dual target internalization and degradation
- (2016) J M Lee et al. ONCOGENE
- Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)
- (2015) Oscar Arrieta et al. Journal of Thoracic Oncology
- Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
- (2015) Mareike Voigt et al. NEOPLASIA
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- Controlled Fab-arm exchange for the generation of stable bispecific IgG1
- (2014) Aran F Labrijn et al. Nature Protocols
- Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration-Effect Data to Support Clinical Development
- (2013) H. Xiang et al. CLINICAL CANCER RESEARCH
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
- (2013) A. F. Labrijn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1
- (2012) Hartmut H. Niemann BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth
- (2012) Paolo Luraghi et al. Frontiers in Pharmacology
- Role of MetMAb (OA-5D5) in c-MET active lung malignancies
- (2011) Mosmi Surati et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- HGF-independent potentiation of EGFR action by c-Met
- (2011) A M Dulak et al. ONCOGENE
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
- (2009) S Agarwal et al. BRITISH JOURNAL OF CANCER
- Targeting the c-MET signaling pathway for cancer therapy
- (2008) Xiangdong Liu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility
- (2008) J. J. Lammerts van Bueren et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now